RxDoctor Payments DataLook up a doctor →

Yvonne Efebera, MD

Hematology · Columbus, OHNPI 1285612986

Payments from drug & device makers

$1,647,860in general payments, 2019–2025

Across 547 payments — averaging $3012.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$772K
  • Pfizer$227K
  • AbbVie$212K
  • Bristol Myers Squibb$199K
  • Pharmacyclics LLC, An Abbvie Company$45K
  • Merck$45K
  • plus $148K from 21 others
$3,150in research payments, 2019–2025

Across 2 payments — averaging $1575.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$2K
  • Sanofi$1K

What the payments were for

  • Consulting fees$88,69752%
  • Speaking & faculty fees$72,17643%
  • Travel & lodging$5,2283%
  • Food & beverage$2,5802%
  • Education$5130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,647,860 in reported general payments places this provider in the 75th percentile of 84 hematology providers in Ohio.

See all hematology providers in Ohio

Medicare billing

Part B allowed, 2024
$94,493
Medicare patients
210
Services billed
760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis47$1,071,370
RevlimidLenalidomide16$248,587
Lenalidomide18$228,851
Potassium Chloride40$1,175
Acyclovir43$973
ValacyclovirValacyclovir Hcl13$708
Gabapentin26$441
Metoprolol Succinate13$263
Oxycodone Hcl11$259
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim54$177
Allopurinol23$164
Pantoprazole Sodium11$132
Levothyroxine Sodium14$119
Dexamethasone13$115
Prednisone15$102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax$226,523$1,071,37047 claims
Bristol Myers SquibbRevlimid$198,544$248,58716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 84 hematology providers in Ohio.

Other hematology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →